Heron Therapeutics, Inc. (HRTX)
NASDAQ: HRTX · Real-Time Price · USD
1.210
+0.020 (1.68%)
At close: Apr 28, 2026, 4:00 PM EDT
1.248
+0.038 (3.17%)
After-hours: Apr 28, 2026, 7:09 PM EDT
Heron Therapeutics Employees
Heron Therapeutics had 128 employees as of December 31, 2025. The number of employees increased by 6 or 4.92% compared to the previous year.
Employees
128
Change (1Y)
6
Growth (1Y)
4.92%
Revenue / Employee
$1,210,188
Profits / Employee
-$157,773
Market Cap
228.25M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 128 | 6 | 4.92% |
| Dec 31, 2024 | 122 | -4 | -3.17% |
| Dec 31, 2023 | 126 | -77 | -37.93% |
| Dec 31, 2022 | 203 | -99 | -32.78% |
| Dec 31, 2021 | 302 | 79 | 35.43% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Replimune Group | 479 |
| Voyager Therapeutics | 141 |
| Adagene | 128 |
| Arcturus Therapeutics Holdings | 111 |
| Keros Therapeutics | 78 |
| Camp4 Therapeutics | 48 |
| ALX Oncology Holdings | 43 |
| Milestone Pharmaceuticals | 38 |
HRTX News
- 1 day ago - Heron Therapeutics to Report First Quarter 2026 Financial Results on Monday, May 11, 2026 - GlobeNewsWire
- 2 months ago - Heron Therapeutics Earnings Call Transcript: Q4 2025 - Transcripts
- 2 months ago - Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results - GlobeNewsWire
- 2 months ago - Heron Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026 - GlobeNewsWire
- 3 months ago - Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF® Largest Contributor to Q4 Growth - GlobeNewsWire
- 5 months ago - Heron Therapeutics Announces Inclusion of APONVIE® (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV) - GlobeNewsWire
- 6 months ago - Heron Therapeutics Earnings Call Transcript: Q3 2025 - Transcripts
- 6 months ago - Heron Therapeutics Announces Q3 2025 Financial Results and Highlights Commercial Progress - GlobeNewsWire